| Molecular formula | C45H55N9O6 |
|---|
| Molecular weight | 818 g/mol |
|---|
| Registered trials | 0 |
|---|
| PubChem CID | 6918245 |
|---|
Regulatory Status
Pralmorelin is classified as an unapproved research compound. There is no FDA-approved label, no approved brand name, and no established indication for human use.
What Pralmorelin Is
Pralmorelin is a synthetic peptide with the molecular formula C45H55N9O6 and a molecular weight of approximately 818. Its structure is identified in PubChem under CID 6918245. No drug label, mechanism of action statement, or pharmacologic class designation is available from regulatory sources for this compound.
Trial Footprint
No registered clinical trials for pralmorelin are currently listed in the data reviewed. There is no trial sample data available to describe study design, phase, or status for this compound.
FAQ
No. Pralmorelin has no FDA-approved label, approved indication, or approved brand name. It is classified as an unapproved research compound.
There is no approved use for pralmorelin. Available data does not include a label, indication, or mechanism of action description.
No registered clinical trials for pralmorelin were found in the data reviewed. This means there is no publicly available trial count, phase, or status information to report.
Pralmorelin is a synthetic peptide with the molecular formula C45H55N9O6 and a molecular weight of approximately 818. It is catalogued in PubChem under CID 6918245.
No adverse event report data is currently available for pralmorelin. Without an approved label or clinical trial record, no side effect profile can be summarized.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem CID 6918245
Updated 2026-11-07